Evidence map›Paper›PMID 39758852›Full record

ArticleEuropean urology open science2025

Trends and Outcomes in Sarcomatoid Renal Cell Carcinoma: Analysis of the National Cancer Data Base.

Luke L Wang, Dhruv Puri, Cesare Saitta, Franklin Liu, Jonathan A Afari, Margaret F Meagher, Kevin Hakimi, Mimi V Nguyen, Aastha Shah, Saeed Ghassemzadeh and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Sarcomatoid Renal Cell Carcinoma: A Clinical Review.Diagnostics (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Luke L WangDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Dhruv PuriDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Cesare SaittaIRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy.
Franklin LiuDepartment of Medicine, University of Arizona College of Medicine, Tuscon, AZ, USA.
Jonathan A AfariDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Margaret F MeagherDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Kevin HakimiDepartment of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Mimi V NguyenDepartment of Urology, Mayo Clinic Arizona, Phoenix, AZ, USA.
Aastha ShahDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Saeed GhassemzadehDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
James D MurphyDepartment of Therapeutic Radiology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Juan Javier-DeslogesDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Rana R McKayMoores UCSD Cancer Center, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Ithaar H DerweeshDepartment of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study. Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC. Trend analyses were conducted using the Cochran-Armitage test. Multivariable analyses were used to assess factors associated with sRCC diagnosis and clinicopathologic characteristics associated with all-cause mortality (ACM). Overall survival (OS) was computed via Kaplan-Meier analysis. Key findings and limitations: sRCC incidence increased from 3.9% in 2010 to 4.1% in 2019 ( Conclusions and clinical implications: The proportion of sRCC cases overall and of stage I sRCC cases increased from 2010 to 2019, supporting the hypothesis of stage migration and the potential for early sarcomatoid dedifferentiation. Further studies on the causal mechanisms underpinning better survival after partial nephrectomy in localized disease and after cytoreductive surgery in metastatic disease are warranted. Patient summary: We analyzed trends and outcomes for a type of aggressive kidney cancer (sarcomatoid renal cell carcinoma, sRCC) using records from the National Cancer Data Base. We found that the percentage of sRCC cases among all kidney cancers increased from 2010 to 2019. Factors such as tumor size and patient age were linked to worse survival. Surgery to remove the cancer was linked to better survival.

Indexed as

National Cancer Data BaseNephrectomyOutcomesPartial nephrectomyRenal cell carcinomaSarcomatoid dedifferentiationStage migrationSurvival

Identifiers

PMID39758852
PMCPMC11699467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.